Clinical syndrome
暂无分享,去创建一个
[1] Heritable pulmonary arterial hypertension , 2020, Definitions.
[2] M. Gassmann,et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. , 2014, European heart journal.
[3] G. Gildengorin,et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes , 2013, Haematologica.
[4] M. Gladwin,et al. Antioxidant therapy for the treatment of pulmonary hypertension. , 2013, Antioxidants & redox signaling.
[5] J. Marks,et al. Superoxide generated at mitochondrial complex III triggers acute responses to hypoxia in the pulmonary circulation. , 2013, American journal of respiratory and critical care medicine.
[6] P. Steendijk,et al. Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. , 2012, American journal of respiratory and critical care medicine.
[7] R. Dweik,et al. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[8] M. Eghbali,et al. Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. , 2012, American journal of respiratory and critical care medicine.
[9] L. Rubin. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? , 2012, American journal of respiratory and critical care medicine.
[10] M. Puhan,et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[11] D. Tsikas. Letter by Tsikas regarding article, "dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase". , 2012, Circulation.
[12] Man Tsuey Tse. Trial watch: Phase III success for first-in-class pulmonary hypertension drug , 2012, Nature reviews. Drug discovery.
[13] P. Gargiulo,et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.
[14] B. Kang,et al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. , 2012, American journal of respiratory cell and molecular biology.
[15] R. Frantz,et al. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[16] H. Palevsky,et al. Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.
[17] M. Gladwin,et al. Reactive oxygen and nitrogen species in pulmonary hypertension. , 2012, Free radical biology & medicine.
[18] A. Torbicki,et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.
[19] R. Benza,et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. , 2012, Chest.
[20] L. Lopes,et al. Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. , 2011, Free radical biology & medicine.
[21] C. Tysk,et al. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. , 2011, Journal of gastrointestinal and liver diseases : JGLD.
[22] Lan Zhao,et al. Safety of sapropterin dihydrochloride (6r–bh4) in patients with pulmonary hypertension , 2011, Experimental lung research.
[23] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[24] S. Suissa,et al. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. , 2010, Circulation.
[25] Gene Kim,et al. Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension: A Basis for Excessive Cell Proliferation and a New Therapeutic Target , 2010, Circulation.
[26] M. Humbert,et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.
[27] E. K. Weir,et al. Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.
[28] G. Raskob,et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.
[29] M. Gladwin,et al. Nitrite Potently Inhibits Hypoxic and Inflammatory Pulmonary Arterial Hypertension and Smooth Muscle Proliferation via Xanthine Oxidoreductase–Dependent Nitric Oxide Generation , 2010, Circulation.
[30] Sanjiv J. Shah,et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.
[31] P. Hassoun,et al. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. , 2009, Circulation.
[32] A. Malik,et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. , 2009, The Journal of clinical investigation.
[33] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[34] J. Stasch,et al. Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension , 2009, ChemMedChem.
[35] F. Parl,et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females , 2009, European Respiratory Journal.
[36] Michael P. Murphy,et al. How mitochondria produce reactive oxygen species , 2008, The Biochemical journal.
[37] N. Rudarakanchana,et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. , 2008, Human molecular genetics.
[38] J. Cogan,et al. Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance , 2008, BMC Medical Genomics.
[39] W. Seeger,et al. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. , 2008, Antioxidants & redox signaling.
[40] H. Beppu,et al. Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension , 2008, Circulation.
[41] M. Rabinovitch. Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.
[42] M. Crabtree,et al. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. , 2008, American journal of physiology. Heart and circulatory physiology.
[43] Crystal Kantores,et al. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[44] Wolfgang M Kuebler,et al. Intravital microscopy of the murine pulmonary microcirculation. , 2008, Journal of applied physiology.
[45] J. Zweier,et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4 , 2007, Proceedings of the National Academy of Sciences.
[46] W. Seeger,et al. Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature , 2007, Circulation research.
[47] D. Curiel,et al. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[48] Raed A Dweik,et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.
[49] J. Cogan,et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[50] R. Brandes,et al. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia , 2006, British journal of pharmacology.
[51] S. Black,et al. Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[52] M. Humbert,et al. Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.
[53] R. Benza,et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.
[54] D. Stewart,et al. Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival: Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension , 2006, Circulation research.
[55] M. Humbert,et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension , 2006, Human mutation.
[56] T. Rabelink,et al. Tetrahydrobiopterin, but Not l-Arginine, Decreases NO Synthase Uncoupling in Cells Expressing High Levels of Endothelial NO Synthase , 2006, Hypertension.
[57] H. Schumacher,et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.
[58] J. Massagué,et al. Smad transcription factors. , 2005, Genes & development.
[59] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[60] E. Jackson,et al. Estradiol Metabolites Attenuate Monocrotaline-Induced Pulmonary Hypertension in Rats , 2005, Journal of cardiovascular pharmacology.
[61] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[62] K. Rockett,et al. Pivotal Role for Endothelial Tetrahydrobiopterin in Pulmonary Hypertension , 2005, Circulation.
[63] J. Dyck,et al. Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.
[64] M. Gladwin,et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator , 2004, Nature Medicine.
[65] R. Tuder,et al. Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle , 2004, Circulation research.
[66] M. Humbert,et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.
[67] M. Vogeser,et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[68] P. V. van Heerden,et al. The selective pulmonary vasodilatory effect of inhaled DETA/NO, a novel nitric oxide donor, in ARDS-a pilot human trial. , 2004, Journal of critical care.
[69] N. Alp,et al. Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[70] James C Moon,et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. , 2004, American heart journal.
[71] R. Trembath,et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.
[72] M. Gladwin,et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation , 2003, Nature Medicine.
[73] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[74] C. Frampton,et al. B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.
[75] Steven M Holland,et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.
[76] U. Janssens,et al. brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.
[77] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[78] S. Archer,et al. Diversity in Mitochondrial Function Explains Differences in Vascular Oxygen Sensing , 2002, Circulation research.
[79] R. Trembath,et al. Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.
[80] J. Joseph,et al. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. , 2002, The Biochemical journal.
[81] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[82] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.
[83] S. Wedgwood,et al. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[84] G. Castro. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[85] S. Narumiya,et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. , 2001, American journal of respiratory and critical care medicine.
[86] N. Voelkel,et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. , 2001, Journal of applied physiology.
[87] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[88] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[89] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[90] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[91] P. Huang,et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.
[92] J. Orens,et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.
[93] M. Yacoub,et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension , 1998, The Journal of pathology.
[94] J B Seward,et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.
[95] W. Auger,et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.
[96] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[97] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.
[98] S. Narumiya,et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. , 1994, The Journal of biological chemistry.
[99] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[100] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[101] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[102] A. Malik,et al. Pulmonary microvascular endothelial cells constitutively release xanthine oxidase. , 1992, Archives of biochemistry and biophysics.
[103] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[104] D. Stewart,et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.
[105] H. Imura,et al. Increased human brain natriuretic peptide in congestive heart failure. , 1990, The New England journal of medicine.
[106] W. Smith,et al. The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.
[107] Sadao Kimura,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.
[108] D. Buff. Primary pulmonary hypertension. , 1987, Annals of internal medicine.
[109] B. Groves,et al. PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY , 1987 .
[110] W. Chung,et al. A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[111] M. Rubenfire,et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[112] D. Bluemke,et al. Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. , 2011, AJR. American journal of roentgenology.
[113] R. Folz,et al. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). , 2006, American journal of physiology. Lung cellular and molecular physiology.
[114] P. Jones,et al. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. , 2000, The Journal of clinical investigation.
[115] S. Kuribayashi,et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.
[116] M. Humbert,et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.
[117] S. Archer,et al. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. , 1996, Cardiovascular research.
[118] F. Haddad,et al. Pulmonary Circulation | April-june 2012 | Vol 2 | No 2 Review Ar Ticle Diagnosis and Management of Pulmonary Hypertension Associated with Left Ventricular Diastolic Dysfunction , 2022 .